Methadone Thornton & Ross

Methadone, the active ingredient in Methadone Thornton & Ross, is an opioid presented as an oral formulation for oral use. It acts as a long‑acting mu‑opioid receptor agonist and is used to treat opioid dependence, reduce withdrawal symptoms, and provide analgesia for chronic pain in adult patients.

GNH USA supplies Methadone Thornton & Ross as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality and regulatory compliance across global markets.

Methadone is an opioid agonist that addresses disorders of the opioid system and severe pain conditions. - Opioid dependence: helps reduce withdrawal symptoms and cravings during maintenance therapy. - Chronic pain: provides long‑acting analgesia for severe, persistent pain. - Cancer‑related pain: offers sustained pain control when other opioids are insufficient.

Methadone can cause a range of adverse reactions, from mild to life‑threatening.

Common Side Effects: - Nausea - Constipation - Dizziness - Sweating - Sedation - Headache

Serious or Rare Side Effects: - Respiratory depression - QT‑interval prolongation leading to arrhythmia - Severe hypotension - Adrenal insufficiency - Allergic reactions (rash, angioedema) - Seizures

Methadone requires careful monitoring due to its potency and pharmacokinetic profile. - Assess respiratory function: monitor for depression, especially after dose changes. - Evaluate cardiac status: obtain baseline ECG to check QT interval. - Avoid abrupt discontinuation: taper gradually to prevent severe withdrawal. - Use caution in hepatic impairment: dose may need adjustment. - Pregnancy and breastfeeding: consult specialist before use. - Store at ambient temperature: keep in original container, protect from moisture and light.

Methadone interacts with several drug classes that can alter its safety or effectiveness.

Major Interactions (Avoid): - CYP3A4 inhibitors (e.g., ketoconazole): increase methadone levels and risk of toxicity. - Central nervous system depressants (e.g., benzodiazepines): additive respiratory depression. - QT‑prolonging agents (e.g., quinidine): heightened risk of cardiac arrhythmia.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin): may reduce methadone efficacy. - Serotonergic drugs (e.g., SSRIs, SNRIs): potential for serotonin syndrome. - Alcohol: can enhance sedation and respiratory effects.